🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT06885073
Recruiting Not applicable

Non-invasive Central Venous Pressure Estimation in Pediatric Patients

NCT06885073 · tracked via the Priya Life Science USA tracker
Sponsor
Compremium AG
Phase
Not applicable
Started
2025-03-10
Last updated
2025-09-18

Condition(s) studied

Central Venous Pressure

Investigational drug(s) / intervention(s)

CPMX2

CPMX2: CPMX2 - Non-invasive pressure estimation

Study summary

Central Venous Pressure (CVP) is a standard parameter for hemodynamic monitoring and is currently measured through the insertion of a catheter. The pediatric population is especially vulnerable to risks associated to this invasive procedure, including infection, thrombosis, and pneumothorax. The proposed pilot study will evaluate safety and preliminary efficacy of a new non-invasive ultrasound-based venous occlusion pressure (VOP) monitoring device (CPMX2) in children equipped with an invasive catheter for CVP monitoring as part of standard of care.

Eligibility

Sex
ALL
Min age
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria * Provision of signed and dated informed consent form * Male or female * Age: birth to 21 years of age * Equipped with a central venous catheter (CVC) for central venous pressure (CVP) monitoring indication as part of standard of care, or undergoing cardiac catheterization. Exclusion Criteria: * Weight less than 2.5kg at the time of enrollment. * Bilateral external jugular veins not accessible due to vascular access or dressing. * Bilateral skin lesion contraindicating neck Ultrasound * Active bleeding * Clinically unstable, per clinical assessment by attending physician and/or surgeon

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Children's National Hospital Washington D.C. District of Columbia Recruiting

More Compremium AG trials in the USA

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06885073 on ClinicalTrials.gov ↗ ← All trials in the USA